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Summary
Anecdotal reports suggest that patients with chronic hepatitis C virus (HCV) hepatitis and overt or occult hepatitis B virus (HBV) coinfection may reactivate HBV when HCV is suppressed or cleared by direct-acting antivirals (DAAs). We assessed the preva- were HCV-RNA negative at week 4 and 98 (94.2%) achieved sustained virological response. All four HBsAg-positive patients treated with NUCs remained HBV-DNA negative, but three of four untreated patients showed an increase in HBV-DNA of 2-3 log without a biochemical flare and achieved HBV-DNA suppression when given NUCs. During or after DAAs, by conventional assay, HBV-DNA remained not detectable in all 37 anti-HBc-positive patients but in three of them (8.1%) HBV-DNA became detectable with a highly sensitive PCR. HBV reactivation is likely to occur in untreated HBV/HCV-coinfected cirrhotic patients when they undergo HCV treatment with DAAs. Pre-emptive therapy with NUCs should be considered in this setting. Anti-HBc-positive patients rarely reactivate HBV without clinical or virological outcomes.
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| INTRODUCTION

Hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection is not uncommon in patients with chronic hepatitis or cirrhosis in countries
where HBV and HCV infection have a high prevalence and in patients Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DAAs, direct-acting antivirals; EGS, esophagogastroscopy; GGT, gamma-glutamyl transferase; HBV, hepatitis B virus; HCV, hepatitis C virus; IFN, interferon; NUCs, nucleos(t)ide analogues; SVR, sustained virological response; US, ultrasound scan.
with at-risk behaviour. Overall, the estimated prevalence of HBV/HCV coinfection ranges from 5% to 20% in HBsAg-positive patients and from 2% to 10% in the HCV positive. 
| PATIENTS AND METHODS
| Statistical analysis
Data were analysed with the SPSS statistical package (version 20.0; SPSS, Chicago, IL, USA). Data for continuous variables are presented as mean and standard deviation (SD) or as median and range, and data for categorical variables as frequency and percentage. Differences between continuous data were analysed by t test, and Yate's continuity correction to chi-square was used for dichotomous or categorical variables.
| RESULTS
One hundred and four patients with HCV cirrhosis started DAA treatment during the enrolment period. Twelve patients had a treated HCC and four patients had a liver transplant in the previous years. At the start of DAA treatment, 95 patients had a Child-Pugh A5-A6 score and nine patients a Child-Pugh B7 score. Eight of these patients (7.7%) were The baseline features of patients are shown in Table 1 and the baseline features of patients regarding the virological status are shown in Table 2 .
We used the DAA regimens shown in HBsAg-positive patients (7 HCV-RNA negative, 87.5%) and 37 patients with previous exposure to HBV (22 HCV-RNA negative, 59.5%).
One patient stopped antiviral therapy because of adverse events, and two patients died during the observation (one patient because of liver failure and one patient because of oesophageal varices bleeding). Regarding the virological response, one patient remained HCV-RNA positive during the treatment and was considered a no responder and two had a virological relapse during the 12 weeks of post-treatment follow-up. In the intention to treat analysis, SVR was achieved in 98 patients (94.2%).
All HBsAg-positive patients were tested negative for HBeAg and anti-HDV. The values of qHBsAg were less than 1000 IU/mL in seven of eight patients. Four of them had been treated with Entecavir for more than 1 year due to HBV-DNA values >20 IU/mL, and had serum HBV-DNA levels <20 IU/mL at the time of starting DAAs for HCV.
Another four HBsAg-positive patients had persistently serum HBV-DNA levels <20 IU/mL and values of qHBsAg less than 1000 IU/mL at six-monthly checks over the preceding years and were classified as "inactive" HBV carriers at the time of starting DAAs, thus not begin
given NUCs. Table 4 shows the virological characteristics and the ther- ALT (IU/mL) 68.5±41.9
Platelets 122 000±68.4
Bilirubin (mg/mL) 1.1±0.5
Albumin (g/mL) 4.1±0.5
Creatinine No patients among the 59 anti-HBc negative had detectable serum HBV-DNA by highly sensitive PCR during or after DAA therapy.
The rate of flares of ALT and HBV-DNA for each of the HBV status has been reported in Table 5 .
| DISCUSSION
Several clinical studies have suggested that HCV and HBV infection interact between themselves in the chronically coinfected patient, 5, 16, 17 usually causing prevalent suppression of HBV infection with lower HBV-DNA levels, decreased HBV-DNA polymerase activity and reduced intrahepatic expression of HBsAg and HBcAg. This could be linked due to the interference between the two viruses replicative mechanisms in a limited replicative space, [18] [19] [20] but also to indirect mechanisms mediated by the innate and/or adaptive host immune responses. 21 Moreover, the balance between the two viruses is known to be unstable and may change over time, with phases of HCV replication prevailing over HBV. 1, 5 Regarding previous exposure to HBV, clinical studies indicate that occult HBV infection is associated with more severe liver damage and higher risk of developing cirrhosis and HCC in HCV infected patients. [22] [23] [24] Moreover, it is also conceivable that HBV replication could be impaired by HCV to the point of determining the state of occult infection 25 In vitro studies suggest a strong inhibitory effect of the HCV "core" protein on HBV replication, 26 but experiments that utilized full-length HBV genomes and HCV replicons did not demonstrate direct interference between the two viruses. In conclusion, as stated by current HCV guidelines, 35 HBV status should be appropriately evaluated by testing for HBsAg, anti-HBc and anti-HBs in all patients before starting a DAA regimen for HCV. For
HBsAg-positive patients with cirrhosis, if not already on treatment
with Entecavir or Tenofovir, should be considered the prophylactic therapy with a NUC before DAA. HBsAg-negative patients with isolated anti-HBc positivity can also reactivate HBV even if this seems a rare event without clinical and virological outcomes. These patients should however be followed closely when undergoing DAA treatment.
These data are not conclusive to indicate prophylaxis with NUCs during therapy with DAAs in all patients with HBV and HCV coinfection, but suggest special attention and precautions in this subset of patients. Further studies, especially in Asian patients, are definitely warranted.
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